Repositioning VU‐0365114 as a novel microtubule‐destabilizing agent for treating cancer and overcoming drug resistance

Author:

Hsieh Yao‐Yu1234,Du Jia‐Ling5,Yang Pei‐Ming34567ORCID

Affiliation:

1. Division of Hematology and Oncology Taipei Medical University Shuang Ho Hospital New Taipei City Taiwan

2. Division of Hematology and Oncology, Department of Internal Medicine, School of Medicine, College of Medicine Taipei Medical University Taipei Taiwan

3. Taipei Cancer Center Taipei Medical University Taipei Taiwan

4. TMU and Affiliated Hospitals Pancreatic Cancer Groups Taipei Medical University Taipei Taiwan

5. Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology Taipei Medical University New Taipei City Taiwan

6. Ph.D. Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology Taipei Medical University New Taipei City Taiwan

7. TMU Research Center of Cancer Translational Medicine Taipei Taiwan

Abstract

Microtubule‐targeting agents represent one of the most successful classes of anticancer agents. However, the development of drug resistance and the appearance of adverse effects hamper their clinical implementation. Novel microtubule‐targeting agents without such limitations are urgently needed. By employing a gene expression‐based drug repositioning strategy, this study identifies VU‐0365114, originally synthesized as a positive allosteric modulator of human muscarinic acetylcholine receptor M5 (M5 mAChR), as a novel type of tubulin inhibitor by destabilizing microtubules. VU‐0365114 exhibits a broad‐spectrum in vitro anticancer activity, especially in colorectal cancer cells. A tumor xenograft study in nude mice shows that VU‐0365114 slowed the in vivo colorectal tumor growth. The anticancer activity of VU‐0365114 is not related to its original target, M5 mAChR. In addition, VU‐0365114 does not serve as a substrate of multidrug resistance (MDR) proteins, and thus, it can overcome MDR. Furthermore, a kinome analysis shows that VU‐0365114 did not exhibit other significant off‐target effects. Taken together, our study suggests that VU‐0365114 primarily targets microtubules, offering potential for repurposing in cancer treatment, although more studies are needed before further drug development.

Funder

Taipei Medical University

Publisher

Wiley

Subject

Cancer Research,Genetics,Molecular Medicine,General Medicine,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3